Clinical Trial Diversity: ‘How Much More Evidence Do We Need To Move Forward?’
This article was originally published in The Gray Sheet
Executive Summary
FDA seeks research ideas and plans to include demographic subgroup analyses in review templates as some stakeholders call for bolder action to change how companies conduct clinical trials.
You may also be interested in...
Products Lacking Good Subgroup Data Shouldn’t Be Approved, Patient, Medical Groups Tell FDA
FDA should more strongly enforce requirements for adequate demographic subgroup representation in clinical trials for devices and other medical products, participants said at an April 1 meeting on collection and analysis of clinical trial subpopulation data to support product registration.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.